Evidence map›Paper›PMID 27197287›Full record

Trial reportCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2016

Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT.

June M Chan, Amy K Darke, Kathryn L Penney, Catherine M Tangen, Phyllis J Goodman, Gwo-Shu Mary Lee, Tong Sun, Sam Peisch, Alex M Tinianow, James M Rae and 4 more

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 59 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. [EEFSEC knockdown inhibits proliferation, migration and invasion of prostate cancer cellsNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2021
    Article
  16. Article
  17. Review
  18. Article
  19. Association betweenDiagnostics (Basel, Switzerland) · 2020
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 1 country.

June M ChanDepartments Of Epidemiology & Biostatistics and Urology, University of CA San Francisco.
Amy K DarkeSWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA.
Kathryn L PenneyDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston MA.
Catherine M TangenSWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA.
Phyllis J GoodmanSWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA.
Gwo-Shu Mary LeeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA.
Tong SunDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA.
Sam PeischChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, MA.
Alex M TinianowDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston MA.
James M RaeDepartment of Internal Medicine, Division of Hematology/Oncology, University of Michigan Cancer Center, Michigan.
Eric A KleinGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.
Ian M ThompsonThe Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX.
Philip W Kantoff *Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA.
Lorelei A Mucci *Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston MA.
Brigham and Women's Hospital · USFred Hutch Cancer Center · USDana-Farber Cancer Institute · USCleveland Clinic · USHarvard University · USMemorial Sloan Kettering Cancer Center · USMichigan Medicine · USThe University of Texas Health Science Center at San Antonio · USUniversity of California, San Francisco · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
SWOG Foreign AccrualsU10CA037429 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BLANKE, CHARLES D., MEYSKENS, FRANK L. · 1985 to 2014
$205.2M
SWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6M
PCPT and SELECT cohorts: Core Infrastructure Support for Cancer Research UM1CA182883 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI TANGEN, CATHERINE M., THOMPSON, IAN M. · 2013 to 2017
$5.2M
Prostate Microenvironmental & Prostate Cancer ProgressionR01CA106947 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHAN, JUNE ML · 2006 to 2009
$1.5M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA106947NCI NIH HHS U10 CA037429NCI NIH HHS UG1 CA189974NCI NIH HHS UM1 CA182883
6 · The paper itself

Abstract

backgroundEpidemiologic studies and secondary analyses of randomized trials supported the hypothesis that selenium and vitamin E lower prostate cancer risk. However, the Selenium and Vitamin E Cancer Prevention Trial (SELECT) showed no benefit of either supplement. Genetic variants involved in selenium or vitamin E metabolism or transport may underlie the complex associations of selenium and vitamin E.

methodsWe undertook a case-cohort study of SELECT participants randomized to placebo, selenium, or vitamin E. The subcohort included 1,434 men; our primary outcome was high-grade prostate cancer (N = 278 cases, Gleason 7 or higher cancer). We used weighted Cox regression to examine the association between SNPs and high-grade prostate cancer risk. To assess effect modification, we created interaction terms between randomization arm and genotype and calculated log likelihood statistics.

resultsWe noted statistically significant (P < 0.05) interactions between selenium assignment, SNPs in CAT, SOD2, PRDX6, SOD3, and TXNRD2, and high-grade prostate cancer risk. Statistically significant SNPs that modified the association of vitamin E assignment and high-grade prostate cancer included SEC14L2, SOD1, and TTPA In the placebo arm, several SNPs, hypothesized to interact with supplement assignment and risk of high-grade prostate cancer, were also directly associated with outcome.

conclusionVariants in selenium and vitamin E metabolism/transport genes may influence risk of overall and high-grade prostate cancer, and may modify an individual man's response to vitamin E or selenium supplementation with regards to these risks. IMPACT: The effect of selenium or vitamin E supplementation on high-grade prostate cancer risk may vary by genotype. Cancer Epidemiol Biomarkers Prev; 25(7); 1050-8. ©2016 AACR.

Indexed as

Genetic VariationAgedBiological TransportBiomarkers, TumorCohort StudiesHumansMaleMiddle AgedNeoplasm GradingPharmacogenomic VariantsPolymorphism, Single NucleotideProportional Hazards ModelsProstatic NeoplasmsRisk FactorsSeleniumVitamin EBiomarkers, TumorSeleniumVitamin E

Identifiers

PMID27197287
PMCPMC5086806
OpenAlexW2345427609

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.